2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Angiotensin-converting Enzyme (ACE)

Related Products

PDF 1.4 MB

Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W585934
    Fructose-phenylalanine
    		Inhibitor
    Fructose-phenylalanine (Fru-Phe) is a non-competitive angiotensin-converting enzyme (ACE) inhibitor (IC50 =0.19 mM) with antioxidant activities. Fructose-phenylalanine forms a stable complex with Zn2+ ions at the ACE active site, blocking the conversion of angiotensin I to II and thereby lowering blood pressure. Fructose-phenylalanine is promising for research of cardiovascular diseases.
    Fructose-phenylalanine
  • HY-101733
    Zabicipril hydrochloride
    		Inhibitor
    Zabicipril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril hydrochloride can be used for the study of blood pressure and peripheral arterial insufficiency.
    Zabicipril hydrochloride
  • HY-117281S
    Moexipril-d5
    		Inhibitor
    Moexipril-d5 is the deuterium labeled Moexipril. Moexipril hydrochloride is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor, which is used for the treatment of hypertension and congestive heart failure.
    Moexipril-d<sub>5</sub>
  • HY-B0279S2
    Ramipril-d4
    		Inhibitor
    Ramipril-d4 is deuterated labeled Ramipril (HY-B0279). Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM.
    Ramipril-d<sub>4</sub>
  • HY-B0382R
    Fosinopril sodium (Standard)
    		Inhibitor
    Fosinopril (sodium) (Standard) is the analytical standard of Fosinopril (sodium). This product is intended for research and analytical applications. Fosinopril Sodium is the ester prodrug of an angiotensin-converting enzyme (ACE) inhibitor, used for the treatment of hypertension and some types of chronic heart failure.
    Fosinopril sodium (Standard)
  • HY-121180
    A-58365B
    		Inhibitor
    A-58365B is an Angiotensin-converting Enzyme (ACE) inhibitor. A-58365B has antihypertensive effects.
    A-58365B
  • HY-P4551
    Hippuryl-His-Leu-OH
    		Substrate
    Hippuryl-His-Leu-OH (N-Benzoyl-Gly-His-Leu) is a specific substrate for angiotensin-converting enzyme (ACE I) and a molecular tool used for ACE activity detection in in vitro experiments. Hippuryl-His-Leu-OH is hydrolyzed by ACE through competitive binding. Under ACE catalysis, Hippuryl-His-Leu-OH undergoes hydrolysis to produce hippuric acid (HA). The amount of HA produced can be used to quantitatively assess ACE activity or screen for ACE inhibitors. The released His-Leu can also react with o-phthalaldehyde or Fluorescamine (HY-D0715) for fluorescence detection. Hippuryl-His-Leu-OH can be applied to the in vitro screening of ACE inhibitors for hypertension and cardiovascular diseases, and is also used in the study of ACE activity changes in physiological and pathological processes such as renal compensatory hypertrophy.
    Hippuryl-His-Leu-OH
  • HY-118264
    MDL-100240
    		Inhibitor
    MDL-100240 is a dual-acting angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. MDL-100240 can significantly lower blood pressure, reverse left ventricular hypertrophy, and effectively prevent hypertrophy and dilatation of the aorta and resistance arteries, with an effect comparable to that of ramipril (HY-B0279). In addition, MDL-100240 can also reduce aldosterone levels, but has no significant effect on atrial natriuretic peptide and cGMP. In 3-month-old transgenic rats, MDL-100240 can reduce adrenomedullin concentrations, prevent and reverse severe hypertension and cardiovascular damage, and enhance bradykinin effects.
    MDL-100240
  • HY-A0043R
    Cilazapril (Standard)
    		Inhibitor
    Cilazapril (Standard) is the analytical standard of Cilazapril (HY-A0043). This product is intended for research and analytical applications. Cilazapril is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril reduces plasma ACE activity. Cilazapril can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure.
    Cilazapril (Standard)
  • HY-P2072
    GF109
    		Inhibitor
    GF109 is a potent parenteral inhibitor of angiotensin converting enzyme (ACE). GF109 has antihypertensive effects.
    GF109
  • HY-114941
    Aladotril
    		Inhibitor
    Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction.
    Aladotril
  • HY-B0331S1
    Enalapril-d3
    		Inhibitor
    Enalapril-d3 (MK-421-d3) is deuterium labeled Enalapril. Enalapril (MK-421) is an angiotensin-converting enzyme (ACE) inhibitor, can be used for hypertensive diseases research.
    Enalapril-d<sub>3</sub>
  • HY-161068
    hACE2/SP-IN-1
    		Inhibitor
    hACE2/SP-IN-1 (compound 7a) is a dual inhibitor of hACE2 and coronavirus spike protein. hACE2/SP-IN-1 can bind to the spike protein and block cell entry, preventing SARS-CoV-2 from infecting human cells.
    hACE2/SP-IN-1
  • HY-117749
    Bisoxatin acetate
    		Inhibitor 98.41%
    Bisoxatin (WY 8138; DB09219) acetate is a laxative agent. Bisoxatin acetate is a stimulant for intestinal peristalsis and has the potential for the research of constipation disorder.
    Bisoxatin acetate
  • HY-Z8381
    Ramipril diketopiperazine
    		Inhibitor
    Ramipril diketopiperazine is an impurity in the ACE inhibitor Ramipril (HY-B0279).
    Ramipril diketopiperazine
  • HY-A0114
    Moexiprilat
    Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.
    Moexiprilat
  • HY-18206S1
    (S)-Lisinopril-d5 sodium
    		Inhibitor
    (S)-Lisinopril-d5 (sodium) (MK-521-d5 (sodium)) is deuterium labeled Lisinopril. Lisinopril (MK-521) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks.
    (S)-Lisinopril-d<sub>5</sub> sodium
  • HY-119195
    I5B2
    		Inhibitor
    I5B2 is an angiotensin I converting enzyme inhibitor (IC50=0.091 μM) that can be isolated from the culture medium of Actinomycete actininadura sp. No. 937ZE-1. I5B2 can be used in the study of hypertension.
    I5B2
  • HY-127026B
    Quinaprilat hydrochloride
    		Inhibitor
    Quinaprilat hydrochloride is an orally active non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrochloride specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat hydrochloride acts as anti-hypertensive agent and vasodilator.
    Quinaprilat hydrochloride
  • HY-175475
    MolPort-010-778-422
    		Inhibitor
    MolPort-010-778-422 is a high-affinity inhibitor targeting the ACE2 receptor of SARS-CoV-2 virus. MolPort-010-778-422 demonstrates excellent antiviral activity (IC50=8.9 nM). MolPort-010-778-422 is promising for research of SARS-CoV-2.
    MolPort-010-778-422
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity